JP2018530591A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530591A5
JP2018530591A5 JP2018519425A JP2018519425A JP2018530591A5 JP 2018530591 A5 JP2018530591 A5 JP 2018530591A5 JP 2018519425 A JP2018519425 A JP 2018519425A JP 2018519425 A JP2018519425 A JP 2018519425A JP 2018530591 A5 JP2018530591 A5 JP 2018530591A5
Authority
JP
Japan
Prior art keywords
carbonyl
dimethoxyphenyl
pyridine
diol
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530591A (ja
JP6837482B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/056769 external-priority patent/WO2017066402A1/en
Publication of JP2018530591A publication Critical patent/JP2018530591A/ja
Publication of JP2018530591A5 publication Critical patent/JP2018530591A5/ja
Application granted granted Critical
Publication of JP6837482B2 publication Critical patent/JP6837482B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519425A 2015-10-14 2016-10-13 Apjアゴニストとしての2,4−ジヒドロキシ−ニコチンアミド Active JP6837482B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562241367P 2015-10-14 2015-10-14
US62/241,367 2015-10-14
US201562270659P 2015-12-22 2015-12-22
US62/270,659 2015-12-22
PCT/US2016/056769 WO2017066402A1 (en) 2015-10-14 2016-10-13 2,4-dihydroxy-nicotinamides as apj agonists

Publications (3)

Publication Number Publication Date
JP2018530591A JP2018530591A (ja) 2018-10-18
JP2018530591A5 true JP2018530591A5 (enExample) 2019-11-21
JP6837482B2 JP6837482B2 (ja) 2021-03-03

Family

ID=57178558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519425A Active JP6837482B2 (ja) 2015-10-14 2016-10-13 Apjアゴニストとしての2,4−ジヒドロキシ−ニコチンアミド

Country Status (20)

Country Link
US (1) US10392347B2 (enExample)
EP (1) EP3362442B1 (enExample)
JP (1) JP6837482B2 (enExample)
KR (1) KR102707502B1 (enExample)
CN (1) CN108368087B (enExample)
AU (1) AU2016340264B2 (enExample)
BR (1) BR112018007395A2 (enExample)
CA (1) CA3001974A1 (enExample)
CL (1) CL2018000953A1 (enExample)
CO (1) CO2018004968A2 (enExample)
EA (1) EA034857B1 (enExample)
ES (1) ES2774945T3 (enExample)
IL (1) IL258577B (enExample)
MX (1) MX376824B (enExample)
PE (1) PE20181197A1 (enExample)
SG (1) SG10201908839QA (enExample)
TW (1) TW201720796A (enExample)
UY (1) UY36949A (enExample)
WO (1) WO2017066402A1 (enExample)
ZA (1) ZA201802451B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193818A (en) 2015-05-20 2022-10-27 Amgen Inc Triazole agonists of the apj receptor
MA41562B1 (fr) 2015-06-03 2019-05-31 Bristol Myers Squibb Co Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
UY37005A (es) 2015-12-04 2017-06-30 Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
KR102742744B1 (ko) 2015-12-16 2024-12-12 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체의 효능제로서의 헤테로아릴히드록시피리미디논
MY189454A (en) 2016-03-24 2022-02-14 Bristol Myers Squibb Co 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
EP3468956B1 (en) 2016-06-14 2021-03-03 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists
CN109641843B (zh) * 2016-06-14 2022-07-19 百时美施贵宝公司 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮
US10669258B2 (en) 2016-10-14 2020-06-02 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonists
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
WO2025153720A1 (en) * 2024-01-19 2025-07-24 Scenic Biotech Bv Pla2g15 inhibitors

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH602664A5 (en) 1973-06-14 1978-07-31 Sandoz Ag 2-Tert. amino-alkylamino-pyrimidine derivs.
ZA835878B (en) * 1982-08-23 1985-03-27 Warner Lambert Co Cardiotonic agents
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
DE4425616A1 (de) * 1994-07-20 1996-01-25 Basf Ag Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
KR100579765B1 (ko) 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
WO2002006242A2 (en) 2000-07-18 2002-01-24 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
US7166595B2 (en) 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
JP2005530806A (ja) 2002-05-23 2005-10-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害薬
JP2004339159A (ja) 2003-05-16 2004-12-02 Sankyo Co Ltd 4−オキソキノリン誘導体を含有する医薬組成物
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US20050197327A1 (en) 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
WO2005060654A2 (en) 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US8367845B2 (en) 2006-04-21 2013-02-05 The Trustees Of Boston University Ionic viscoelastics and viscoelastic salts
JP2007308441A (ja) * 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
WO2008052863A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur umsetzung von 1,3-hetero-aromatischen 2-carboxylaten mit wasser
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
WO2008103277A2 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
US8415321B2 (en) 2008-04-15 2013-04-09 Raymond F. Schinazi Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections
US20110253929A1 (en) 2008-12-22 2011-10-20 Basf Se Mixtures of hydrophobic and hydrophilic ionic liquids and use thereof in liquid ring compressors
US9040538B2 (en) 2009-05-21 2015-05-26 Universite Laval Pyrimidines as novel therapeutic agents
EP2604260B1 (en) 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
KR20140034256A (ko) 2011-05-31 2014-03-19 메르크 파텐트 게엠베하 히드리도-트리시아노-보레이트 음이온을 포함하는 화합물
EP2715858A1 (en) 2011-05-31 2014-04-09 Merck Patent GmbH Electrolyte formulations
US20140005181A1 (en) * 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
WO2014004676A1 (en) 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns
ES2623528T3 (es) * 2012-09-21 2017-07-11 Sanofi Derivados de amida de ácido benzoimidazolcarboxílico para tratar enfermedades metabólicas o cardiovasculares
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
PT3421462T (pt) 2013-06-27 2023-06-29 Pfizer Compostos heteroaromáticos e a sua utilização como ligandos de d1 de dopamina
WO2014207100A1 (en) 2013-06-27 2014-12-31 Basf Se A process for coating paper with cellulose using a solution containing cellulose
CN106029804B (zh) 2013-11-29 2019-09-24 普罗奥尼克股份有限公司 使用微波辐射使粘合剂固化的方法
US10570128B2 (en) 2014-05-28 2020-02-25 Sanford Burnham Prebys Medical Discovery Institute Agonists of the apelin receptor and methods of use thereof
WO2015188073A1 (en) * 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
MX391647B (es) 2015-04-24 2025-03-21 Shionogi & Co Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende.
MY193818A (en) 2015-05-20 2022-10-27 Amgen Inc Triazole agonists of the apj receptor
MA41562B1 (fr) 2015-06-03 2019-05-31 Bristol Myers Squibb Co Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
EP3380970B1 (en) 2015-11-24 2023-01-04 Sanford Burnham Prebys Medical Discovery Institute Novel azole derivatives as apelin receptor agonist
UY37005A (es) 2015-12-04 2017-06-30 Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
KR102742744B1 (ko) 2015-12-16 2024-12-12 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체의 효능제로서의 헤테로아릴히드록시피리미디논
MY189454A (en) 2016-03-24 2022-02-14 Bristol Myers Squibb Co 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
EP3468956B1 (en) 2016-06-14 2021-03-03 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists
CN109641843B (zh) 2016-06-14 2022-07-19 百时美施贵宝公司 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮
US10669258B2 (en) 2016-10-14 2020-06-02 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonists

Similar Documents

Publication Publication Date Title
JP2018530591A5 (enExample)
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
RU2485114C2 (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
JP2018535999A5 (enExample)
JP2018118992A5 (enExample)
JP2019509319A5 (enExample)
JP2020515575A5 (enExample)
JP2019537571A5 (enExample)
JP2017500364A5 (enExample)
JP2007510689A5 (enExample)
RU2009121564A (ru) Азаадамантановые производные и способы применения
JP2011503166A5 (enExample)
JP2013545744A5 (enExample)
RU2017124425A (ru) Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg
JP2018524343A5 (enExample)
JP2019518036A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
RU2008141761A (ru) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
RU2008126398A (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpti)
JP2015528022A5 (enExample)
JP2014062093A5 (enExample)
JP2016519096A5 (enExample)
RU2017125520A (ru) Соединения, ингибирующие parg
RU2014139601A (ru) Ингибиторы серин/треониновых киназ
RU2012116207A (ru) Производные индола в качестве модуляторов crac